Is RET p.Cys618= (c.1854C>T) pathogenic?

RET p.Cys618= (c.1854C>T) is classified Benign/Likely benign in RET (ClinVar, Multiple submitters, 2 submitters; last evaluated 2025-02-26). Very rare (popmax 8.48e-05%, nfe); Associated with multiple endocrine neoplasia type 2A.

What condition is associated with RET p.Cys618= (c.1854C>T)?

RET p.Cys618= (c.1854C>T) is associated with multiple endocrine neoplasia type 2A, hereditary neoplastic syndrome (ClinVar).

How common is RET p.Cys618= (c.1854C>T) in the general population?

RET p.Cys618= (c.1854C>T) is very rare (popmax 8.48e-05%, nfe) (gnomAD).

How is Multiple endocrine neoplasia type 2 inherited?

Typically Autosomal dominant (Orphanet). A genetic counselor can assess individual risk for a family.

RET p.Cys618=

c.1854C>T · VCV3788338

Benign/Likely benign Multiple submitters

Classification

Benign/Likely benign

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 2 submitters

gnomAD v4.1

Rare

very rare (popmax 8.48e-05%, nfe)

Conditions

multiple endocrine neoplasia type 2A

Computational evidence

Protein change
Missense predictors do not apply to this variant type; conservation carries the signal.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP -0.019	GERP -0.54, phastCons 0.77
Overall
CADD	7.531	PHRED · no single calibrated threshold — expert panels disagree

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 8.48e-05% European (non-Finnish) · 1/1,179,886 alleles

Overall 0.000657% 1/152,170 alleles · very rare

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: RET
Protein: p.Cys618=
Coding: c.1854C>T
MANE Select: NM_020975
Type: single nucleotide variant
Location: chr10:43113650 (GRCh38)
Gene constraint: LOEUF 0.24 · pLI 1.00 · ClinGen HI 3/3 (gnomAD)
Structure: AlphaFold pLDDT 79.27 · 34 PDB
Residue 618: a UniProt-annotated variant site (in men2a and mtc; familial form); a UniProt-annotated variant site (in men2a); a UniProt-annotated variant site (in men2a, mtc and hscr1); a UniProt-annotated variant site (in men2a, hscr1 and mtc; familial and sporadic forms); a disulfide bond

Full RET gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

multiple endocrine neoplasia type 2A — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary neoplastic syndrome

For Multiple endocrine neoplasia type 2 (Orphanet):

Inheritance: Autosomal dominant
Onset: Adolescent, Adult, Childhood, Infancy
Prevalence: 1-9 / 100 000 (Europe)

Similar variants

RET p.Cys618Arg Pathogenic/Likely pathogenic ★★ same residue
RET p.Cys618Gly Pathogenic ★★ same residue
RET p.Cys618Phe Pathogenic ★★ same residue
RET p.Cys618Ser Pathogenic ★★ same residue
RET p.Cys618Tyr Pathogenic ★★ same residue
RET c.1759+1G>A Pathogenic/Likely pathogenic ★★ same condition
RET p.Arg873Trp Likely pathogenic ★★ same condition
RET p.Asp631Tyr Pathogenic ★★ ⚠ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/ret-p-cys618 (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown